<DOC>
	<DOC>NCT00127842</DOC>
	<brief_summary>The overall objective of the study was to describe the long-term effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting.</brief_summary>
	<brief_title>REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Presence of psoriasis or previous evidence of psoriasis documented by a dermatologist as part of usual care At least one of the following forms of psoriatic arthritis (PsA): Distal interphalangeal (DIP) involvement (inflammatory) Polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis Arthritis mutilans Asymmetric peripheral arthritis or Spinal involvement Active psoriatic arthritis at the time of the study enrollment Patients must demonstrate greater than 3 swollen joints and greater than 3 tender/painful joints Greater than 18 years of age at the time of consent Able to start etanercept therapy per the approved product monograph Informed consent must be provided before any study specific procedures are performed Active infections at time of initiating Enbrel® therapy Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the study medication A malignancy, other than basal cell carcinoma of the skin or, in situ carcinoma of the cervix, within the past 5 years Known hypersensitivity to etanercept or any of its components Patients receiving, or who have received: Remicade® (infliximab) in the previous 3 months or Humira® (adalimumab) in the previous 3 months or Kineret® (anakinra) in the previous 15 days Patients receiving or who have received etanercept Treatment with any investigational therapy in the 30 days prior to enrollment or during the study Active guttate, erythrodermic or pustular psoriasis at the time of screening Presence of any significant and uncontrolled medical condition, which in the Investigator's opinion, precludes the use of etanercept as outlined in the product monograph Sepsis or at risk of septic syndrome Patients not available for followup assessment Concerns for subject's compliance with the protocol procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>PsA</keyword>
	<keyword>Commercial product</keyword>
	<keyword>American College of Rheumatology</keyword>
	<keyword>ACR/PASI</keyword>
</DOC>